Oxcarbazepine Causes Hyponatremia More Frequently Than Carbamazepine
Oxcarbazepine has approximately double the incidence of hyponatremia compared to carbamazepine, with clinically significant hyponatremia (sodium <125 mmol/L) occurring in 2.5% of oxcarbazepine-treated patients versus 0% in carbamazepine-treated patients in controlled trials. 1
Comparative Incidence Data
The evidence consistently demonstrates oxcarbazepine's higher risk profile:
FDA-labeled data: In 14 controlled epilepsy studies with 1,524 patients, 2.5% of oxcarbazepine patients developed sodium <125 mmol/L versus none on carbamazepine 1
Large cohort studies: Among 1,421 patients, hyponatremia (Na+ ≤134 mEq/L) occurred in 46% on oxcarbazepine versus 26% on carbamazepine. Severe hyponatremia (Na+ ≤128 mEq/L) occurred in 22% on oxcarbazepine versus 7% on carbamazepine 2
Cross-sectional analysis: In 548 patients, hyponatremia frequency was 29.9% with oxcarbazepine versus 13.5% with carbamazepine (p<0.0001), with severe hyponatremia in 12.4% versus 2.8% respectively (p<0.001) 3
Pediatric data: When carbamazepine was directly replaced with oxcarbazepine in 27 children, hyponatremia increased from 3.7% to 22.2% 4
Clinical Significance
Most hyponatremia cases are asymptomatic but require monitoring. Among symptomatic cases, 48% of patients experienced symptoms, though only 3% required hospital admission 2. The FDA label notes that while most patients were asymptomatic in trials, frequent monitoring and interventions (dose reduction, discontinuation, fluid restriction) may have prevented more severe events 1.
Risk Factors for Both Drugs
Key risk factors apply to both medications but confer higher absolute risk with oxcarbazepine:
- Age >40 years: Most consistent predictor across studies 2, 3
- High serum drug levels: Dose-dependent relationship 2
- Concomitant antiepileptic drugs: Polypharmacy increases risk 2
- Female gender: Specific risk factor for oxcarbazepine 2
- Duration of therapy: Each year of oxcarbazepine increases hyponatremia risk 1.3-fold 5
Monitoring Algorithm
Measure serum sodium at baseline, during the first 3 months of treatment (when most cases occur), and whenever symptoms develop 1. Symptoms suggesting hyponatremia include nausea, malaise, headache, lethargy, confusion, obtundation, or increased seizure frequency 1.
For patients on oxcarbazepine specifically:
- Check sodium more frequently in patients >40 years old
- Monitor closely when combining with other sodium-lowering medications
- Consider more frequent checks in female patients
- Reassess sodium levels with any dose escalation
Important Caveat
Patients who developed hyponatremia on carbamazepine have significantly increased risk of hyponatremia when switched to oxcarbazepine, suggesting individual susceptibility 2. If carbamazepine was discontinued due to hyponatremia, oxcarbazepine should be used with extreme caution or avoided entirely.
The evidence from FDA labeling 1, multiple large cohort studies 2, 3, and pediatric data 4 uniformly demonstrates oxcarbazepine's approximately 2-fold higher risk of hyponatremia compared to carbamazepine, with both higher overall incidence and greater severity when it occurs.